Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more
Procter & Gamble Health Limited (PGHL) - Net Assets
Latest net assets as of September 2025: ₹6.20 Billion INR
Based on the latest financial reports, Procter & Gamble Health Limited (PGHL) has net assets worth ₹6.20 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹8.94 Billion) and total liabilities (₹2.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹6.20 Billion |
| % of Total Assets | 69.29% |
| Annual Growth Rate | 4.91% |
| 5-Year Change | -23.7% |
| 10-Year Change | -9.23% |
| Growth Volatility | 29.44 |
Procter & Gamble Health Limited - Net Assets Trend (2003–2024)
This chart illustrates how Procter & Gamble Health Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual net assets of Procter & Gamble Health Limited from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₹5.37 Billion | -0.24% |
| 2023-12-31 | ₹5.38 Billion | -28.32% |
| 2022-12-31 | ₹7.51 Billion | +21.80% |
| 2021-12-31 | ₹6.16 Billion | -12.39% |
| 2020-12-31 | ₹7.04 Billion | -22.36% |
| 2019-12-31 | ₹9.06 Billion | -41.15% |
| 2018-12-31 | ₹15.40 Billion | +110.04% |
| 2017-12-31 | ₹7.33 Billion | +13.60% |
| 2016-12-31 | ₹6.45 Billion | +9.11% |
| 2015-12-31 | ₹5.92 Billion | +6.72% |
| 2014-12-31 | ₹5.54 Billion | +5.98% |
| 2013-12-31 | ₹5.23 Billion | +8.14% |
| 2012-12-31 | ₹4.84 Billion | +17.94% |
| 2011-12-31 | ₹4.10 Billion | +18.38% |
| 2010-12-31 | ₹3.46 Billion | -25.87% |
| 2009-12-31 | ₹4.67 Billion | +3.52% |
| 2008-12-31 | ₹4.51 Billion | +6.74% |
| 2007-12-31 | ₹4.23 Billion | +7.60% |
| 2006-12-31 | ₹3.93 Billion | +31.83% |
| 2005-12-31 | ₹2.98 Billion | +20.13% |
| 2004-12-31 | ₹2.48 Billion | +26.46% |
| 2003-12-31 | ₹1.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Procter & Gamble Health Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 509230000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹5.09 Billion | 94.84% |
| Common Stock | ₹166.00 Million | 3.09% |
| Other Components | ₹111.30 Million | 2.07% |
| Total Equity | ₹5.37 Billion | 100.00% |
Procter & Gamble Health Limited Competitors by Market Cap
The table below lists competitors of Procter & Gamble Health Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DRI Healthcare Trust
TO:DHT-U
|
$450.44 Million |
|
Guangdong Wencan Die Casting Co Ltd
SHG:603348
|
$450.58 Million |
|
Gevo Inc
NASDAQ:GEVO
|
$450.69 Million |
|
Malibu Boats Inc
NASDAQ:MBUU
|
$450.74 Million |
|
Tinexta S.p.A.
LSE:0RIW
|
$450.40 Million |
|
DOM DEVELOPMENT SE.A.ZY 1
F:6WV
|
$450.29 Million |
|
Investis Holding SA
SW:IREN
|
$450.20 Million |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
$450.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Procter & Gamble Health Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,382,400,000 to 5,369,600,000, a change of -12,800,000 (-0.2%).
- Net income of 2,511,900,000 contributed positively to equity growth.
- Dividend payments of 2,324,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 5,216,400,000.
- Other factors increased equity by 5,015,700,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹2.51 Billion | +46.78% |
| Dividends Paid | ₹2.32 Billion | -43.28% |
| Other Comprehensive Income | ₹-5.22 Billion | -97.15% |
| Other Changes | ₹5.02 Billion | +93.41% |
| Total Change | ₹- | -0.24% |
Book Value vs Market Value Analysis
This analysis compares Procter & Gamble Health Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.27x to 15.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | ₹116.39 | ₹4920.00 | x |
| 2004-12-31 | ₹147.19 | ₹4920.00 | x |
| 2005-12-31 | ₹176.82 | ₹4920.00 | x |
| 2006-12-31 | ₹233.10 | ₹4920.00 | x |
| 2007-12-31 | ₹250.81 | ₹4920.00 | x |
| 2008-12-31 | ₹267.71 | ₹4920.00 | x |
| 2009-12-31 | ₹278.63 | ₹4920.00 | x |
| 2010-12-31 | ₹208.69 | ₹4920.00 | x |
| 2011-12-31 | ₹247.05 | ₹4920.00 | x |
| 2012-12-31 | ₹291.37 | ₹4920.00 | x |
| 2013-12-31 | ₹315.09 | ₹4920.00 | x |
| 2014-12-31 | ₹333.93 | ₹4920.00 | x |
| 2015-12-31 | ₹356.37 | ₹4920.00 | x |
| 2016-12-31 | ₹388.85 | ₹4920.00 | x |
| 2017-12-31 | ₹441.74 | ₹4920.00 | x |
| 2018-12-31 | ₹927.83 | ₹4920.00 | x |
| 2019-12-31 | ₹545.56 | ₹4920.00 | x |
| 2020-12-31 | ₹423.94 | ₹4920.00 | x |
| 2021-12-31 | ₹371.40 | ₹4920.00 | x |
| 2022-12-31 | ₹452.36 | ₹4920.00 | x |
| 2023-12-31 | ₹324.25 | ₹4920.00 | x |
| 2024-12-31 | ₹323.49 | ₹4920.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Procter & Gamble Health Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 46.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.62%
- • Asset Turnover: 1.53x
- • Equity Multiplier: 1.48x
- Recent ROE (46.78%) is above the historical average (22.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 20.20% | 10.89% | 1.31x | 1.42x | ₹200.15 Million |
| 2004 | 28.60% | 18.89% | 1.15x | 1.32x | ₹461.72 Million |
| 2005 | 26.43% | 20.00% | 1.02x | 1.30x | ₹489.77 Million |
| 2006 | 33.93% | 40.47% | 0.69x | 1.22x | ₹940.47 Million |
| 2007 | 16.27% | 21.86% | 0.64x | 1.16x | ₹265.30 Million |
| 2008 | 13.96% | 16.18% | 0.69x | 1.24x | ₹178.71 Million |
| 2009 | 14.01% | 13.84% | 0.83x | 1.22x | ₹187.51 Million |
| 2010 | 18.24% | 12.41% | 1.18x | 1.24x | ₹285.38 Million |
| 2011 | 15.53% | 11.42% | 1.12x | 1.22x | ₹226.72 Million |
| 2012 | 16.21% | 11.94% | 1.10x | 1.23x | ₹300.34 Million |
| 2013 | 10.68% | 7.02% | 1.23x | 1.24x | ₹35.77 Million |
| 2014 | 7.80% | 4.99% | 1.22x | 1.28x | ₹-122.10 Million |
| 2015 | 9.05% | 5.71% | 1.20x | 1.33x | ₹-55.95 Million |
| 2016 | 12.26% | 7.97% | 1.12x | 1.37x | ₹145.84 Million |
| 2017 | 12.81% | 13.45% | 0.70x | 1.35x | ₹205.84 Million |
| 2018 | 54.46% | 98.79% | 0.48x | 1.14x | ₹6.85 Billion |
| 2019 | 18.31% | 18.67% | 0.76x | 1.30x | ₹752.84 Million |
| 2020 | 25.12% | 17.53% | 1.02x | 1.40x | ₹1.06 Billion |
| 2021 | 31.23% | 17.28% | 1.25x | 1.45x | ₹1.31 Billion |
| 2022 | 30.56% | 18.66% | 1.12x | 1.47x | ₹1.54 Billion |
| 2023 | 37.34% | 17.46% | 1.45x | 1.48x | ₹1.47 Billion |
| 2024 | 46.78% | 20.62% | 1.53x | 1.48x | ₹1.97 Billion |
Industry Comparison
This section compares Procter & Gamble Health Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Procter & Gamble Health Limited (PGHL) | ₹6.20 Billion | 20.20% | 0.44x | $450.44 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |